• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Surgical Endoscopy >Symptomatic outcomes of laparoscopic antireflux surgery in patients eligible for endoluminal therapies.
【24h】

Symptomatic outcomes of laparoscopic antireflux surgery in patients eligible for endoluminal therapies.

机译：有资格进行腔内治疗的患者的腹腔镜抗反流手术的症状结果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: This study compared clinical outcomes after laparoscopic antireflux surgery (LARS) in patients with gastroesophageal reflux disease (GERD) who would be eligible for endoluminal therapies (ET) with those in patients who would be excluded from ET. METHODS: From 1995 to the present, 459 patients who underwent LARS were analyzed prospectively. Of these, 117 patients (25%) without preoperative dysphagia, stricture, esophagitis worse than grade 2 or hiatal hernia larger than 2 cm were considered potential candidates for ET (group 1). By these criteria, 342 patients (75%) were not eligible for ET (group 2). Medication use and GERD symptoms were evaluated and compared between the two groups. RESULTS: Perioperative outcomes including duration of operation, morbidity, length of hospital stay and return to work were similar in the two groups. Although LARS significantly reduced medication use and GERD symptoms in both groups during a mean follow-up period longer than 2 years, there were no outcome differences between groups 1 and 2. The reported improvement in esophageal symptoms and overall satisfaction was 90% or more in both groups. CONCLUSIONS: The findings show that LARS is an effective treatment option in patients with GERD whether they are candidates for ET or not. In patients with uncomplicated GERD who currently meet inclusion criteria for ET, LARS provides excellent symptom relief and marked reduction in medication use during a mean follow-up period longer than 2 years.
机译：背景：本研究比较了有资格接受腔内治疗（ET）的胃食管反流病（GERD）患者与腹腔镜反流手术（LARD）患者的腹腔镜抗返流手术（LARS）的临床结局。方法：从1995年至今，对459例行LARS的患者进行了前瞻性分析。其中117例（25％）无术前吞咽困难，狭窄，食管炎不及2级或食管裂孔疝大于2 cm的患者被认为是ET的潜在候选人（第1组）。根据这些标准，有342名患者（75％）不符合ET资格（第2组）。对两组的药物使用和GERD症状进行了评估和比较。结果：两组患者的围手术期结局包括手术持续时间，发病率，住院时间和重返工作组相似。尽管LARS在平均随访期超过2年期间显着降低了两组的药物使用和GERD症状，但第1组和第2组之间没有结局差异。据报道，食管症状改善和总体满意度在90％以上。两组。结论：研究结果表明，无论是否为ET候选人，LARS都是GERD患者的有效治疗选择。对于目前符合ET纳入标准的GERD并发患者，在平均随访期超过2年的情况下，LARS可以缓解症状，并显着减少用药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号